Abstract
Nicorandil (NIC) is a calcium channel blocker, which has been widely used in the treatment of coronary heart disease (CHD). Although NIC has shown good efficacy and safety clinically, there are still some unresolved issues with its therapeutic mechanism and pathway of action. Studies in recent years have shown that the clinical application of NIC in the treatment of CHD has made new progress, such as being widely used in stable angina pectoris (AP), myocardial infarction, and percutaneous coronary intervention (PCI). In this article, we discuss the new progress of NIC in the treatment of CHD.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
